Apr 30, 2018
Seegene has participated from April 21st to 24th in the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) in Madrid, Spain.
In this congress Seegene has presented the 'All-in-One' platform which allows one consolidated platform for all molecular diagnostic tests, and their broad test menu including infectious diseases and drug resistance which also of course can be applied thereon. Moreover, Seegene introduced “All-in-One” platform based SGSTAR that can be tested and reported on the day, and a combination test that can satisfy for both patients and hospitals because several different types of diagnosis test can be done by using same sample and method.
SGSTAR is a test system which combines the strength of Seegene’s multiplex technology and advantages of combination tests that enables testing of various molecules under the same conditions, regardless of sample type or test menu. Seegene also presented the case studies and its utilization using SGSTAR for the combination test of gastrointestinal and respiratory infectious diseases in the symposium that they held with the theme of ‘Expansion of the All-in-One platform, a solution for diagnosis of infectious diseases’. Furthermore, The clinical cases of new products Allplex™ Entero-DR Assay ? detects and identifies 8 antibiotic resistance genes which can monitor 3 major resistances of antibiotics (carbapenem, vancomycin and extended spectrum of beta-lactam) and Allplex™ Meningitis Assays - detects and identifies 12 viruses and 6 bacteria causing meningitis, have been presented, and the participants showed the great interest in examining multiple drug resistant genes in a single sample, as well as its high accuracy of result over conventional testing methods. Consequently, the results of the survey analysis on the participants of the symposium showed, the 95% of the respondents answered that they were ‘interested in the combined test' and 77% among them said that they 'want to participate in the assessment on the combined test', therefore, there was verified the positive market reaction on the adoption of combined test.
Marking its 28th anniversary, the ECCMID is Europe's largest clinical microbiology and infectious disease congress on current diagnosis and treatment of infectious diseases, new infectious diseases, infection outbreak control, and drug resistance. This year, 12,900 people from 125 countries attended, with the attendance growing annually due to the rapid expansion of the field of in vitro diagnostic testing, including molecular diagnostics.